Literature for ABT-341 (S09.003 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2006
1. [YEAR:2-11-2006]Pei,Z., Li,X., von Geldern,T.W., Madar,D.J., Longenecker,K., Yong,H., Lubben,T.H., Stewart,K.D., Zinker,B.A., Backes,B.J., Judd,A.S., Mulhern,M., Ballaron,S.J., Stashko,M.A., Mika,A.K., Beno,D.W., Reinhart,G.A., Fryer,R.M., Preusser,L.C., Kempf-Grote,A.J., Sham,H.L. and Trevillyan,J.M.
   Discovery of ((4R,5S)-5-Amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
   J Med Chem49, 6439-6442. PubMed  Europe PubMed DOI  I